Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy

Cancer Gene Therapy

Volumn 12, Issue 12, 2005, Pages 954-962

  Heideman, Daniëlle A M ^a   Overmeer, Renée M ^a   Van Beusechem, Victor W ^a   Lamers, Wouter H ^b   Hakvoort, Theodorus B M ^b   Snijders, Peter J F ^a   Craanen, Mikael E ^a   Offerhaus, G Johan A ^b   Meijer, Chris J L M ^a   Gerritsen, Winald R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; c MET; Hepatocyte growth factor; Invasion; Tumor growth

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; PROTEIN; PROTEIN NK4; UNCLASSIFIED DRUG;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EVALUATION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MET; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 27744557794     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700856     Document Type: Article

References (46)

1. Curley SA, Jones DV. Management of hepatocellular carcinoma. In: Meyers MA ed. Neoplasms of the digestive tract: imaging, staging and management. 1st edn. Philadelphia: Lippincott-Raven; 1998: 93-109.
2. Prieto J, Herraiz M, Sangro B, et al. The promise of gene therapy in gastrointestinal and liver diseases. Gut. 2003; 52(Suppl 2):49-54.
3. Date K, Matsumoto K, Shimura H, et al. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 1997;420:1-6.
4. Kuba K, Matsumoto K, Date K, et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000;60:6737-6743.
5. Date K, Matsumoto K, Kuba K, et al. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 1998;17: 3045-3054.
6. Jiang WG, Hiscox SE, Parr C, et al. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res. 1999;5:3695-3703.
7. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/ angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003;94:321-327.
8. Maemondo M, Narumi K, Saijo Y, et al. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther. 2002;5:177-185.
9. Hirao S, Yamada Y, Koyama F, et al. Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther. 2002;9:700-707.
10. Maehara N, Nagai E, Mizumoto K, et al. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis. 2002;19:417-426.
11. Saimura M, Nagai E, Mizumoto K, et al. Intraperitoneal injection of adenovirus-media ted NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther. 2002;9:799-806.
12. Heideman DAM, van Beusechem VW, Bloemena E, et al. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J Gene Med. 2004;6:317-327.
13. Fujiwara H, Kubota T, Amaike H, et al. Suppression of peritoneal implantation of gastric cancer cells by adenovirus vector-mediated NK4 expression. Cancer Gene Ther. 2005; 12:206-216.
14. Ueda K, Iwahashi M, Matsuura I, et al. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur J Cancer. 2004;40: 2135-2142.
15. Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres. Pharm Res. 2004;21:1109-1118.
16. Tanaka T, Shimura H, Sasaki T, et al. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther. 2004; 11:431-440.
17. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther. 2004;11:419-430.
18. Brockmann MA, Papadimitriou A, Brandt M, et al. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res. 2003;9:4578-4585.
19. Davies G, Mason MD, Martin TA, et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer. 2003;106:348-354.
20. Martin TA, Parr C, Davies G, et al. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis. 2003;24:1317-1323.
21. Luo YQ, Wu MC, Cong WM. Gene expression of hepatocyte growth factor and its receptor in HCC and nontumorous liver tissues. World J Gastroenterol. 1999;5:119-121.
22. Tavian D, De Petro G, Benetti A, et al. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer. 2000;87:644-649.
23. Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver. 1999; 19:151-159.
24. Ljubimova JY, Petrovic LM, Wilson SE, et al. Expression of HGF, its receptor c-met, c-myc and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem. 1997; 45:79-87.
25. Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor c-met protooncogene in hepatocellular carcinoma. Hepatology. 1997;25: 619-623.
26. Sakata H, Takayama H, Sharp R, et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ.. 1996;7:1513-1523.
27. Horiguchi N, Takayama H, Toyoda M, et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene. 2002;21:1791-1799.
28. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett. 1991;291:229-232.
29. Shiota G, Rhoads DB, Wang TC, et al. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA. 1992;89:373-377.
30. Miyazaki M, Gohda E, Tsuboi S, et al. Human hepatocyte growth factor stimulates the growth of HUH-6 clone 5 human hepatoblastoma cells. Cell Biol Int Rep. 1992;16: 145-154.
31. Neaud V, Faouzi S, Guirouilh J, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology. 1997;26:1458-1466.
32. Liu ML, Mars WM, Michalopoulos GK. Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine. Carcinogenesis. 1995;16:841-843.
33. Shiota G, Kawasaki H, Nakamura T, et al. Inhibitory effect of hepatocyte growth factor on metastasis of hepatocellular carcinoma in transgenic mice. Res Commun Mol Pathol Pharmacol. 1996;91:33-39.
34. Santoni-Rugiu E, Preisegger KH, Kiss A, et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA. 1996;93:9577-9582.
35. Fontijn R, Hop C, Brinkman HJ, et al. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res. 1995;216:199-207.
36. Heideman DAM, Snijders PJF, Bloemena E, et al. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J. Pathol. 2001;194:428-435.
37. Borset M, Lien E, Espevik T, et al. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem. 1996;271: 24655-24661.
38. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997;57:5391-5398.
39. Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13:41-59.
40. Nakabayashi M, Morishita R, Nakagami H, et al. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia. 2003;46:115-123.
41. Kuba K, Matsumoto K, Ohnishi K, et al. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun. 2000;279:846-852.
42. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol. 2000;18:723-727.
43. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest.. 2000;105:847-851.
44. Motoi F, Sunamura M, Ding L, et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther. 2000;11: 223-235.
45. Maemondo M, Saijo Y, Narumi K, et al. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res. 2004;64:4611-4620.
46. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA. 1998;95:9065-9066.